

## Disclosures

ASRS adheres to the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**The Planning Committee members below have responded that they have no relevant financial relationships with ineligible entities:**

Planning Committee Members:

**Michael Lai, MD, PhD**

**The Planning Committee members below have disclosed the following financial relationships with ineligible entities:**

Planning Committee Members: Name of Ineligible Company/Nature of Relationship

**Robert Avery, MD:** Alcon Laboratories, Consultant, Stock; Alimera, Consultant; Allergan, Consultant; Amgen, Consultant; Apellis, Consultant, Stock; Bausch+Lomb, Consultant; Clearside, Consultant; EyePoint, Consultant, Stock; Genentech, Consultant; Aldeyra, Stock; Novartis, Consultant, Stock; Ocular Therapeutics, Consultant; Outlook, Consultant, Stock; Regeneron Pharmaceuticals, Stock; Replenish, Royalties or Patent Beneficiary, Stock, Santen, Consultant; Revana, Advisory Board Member, Stock; Pr3vent, Board of Directors; Cardinal Health, Consultant; Coherus, Consultant; AsclepiX, Consultant; Glaukos, Consultant; Tenpoint, Consultant; Visionary Ventures, Consultant, Stock; Infocus Capital, Consultant, Stock; Adverum, Consultant; Kodiak, Stock; ProQR Therapeutics, Stock; RegenXbio, Consultant, Principal Investigator; Oyster Point, Consultant

**Geoffrey Emerson, MD, PhD, FASRS:** Regeneron, Stock; Novartis, Stock; Glaukos, Stock; Roche, Stock; Regenxbio, Stock; Johnson & Johnson, Stock; Pfizer, Stock; Ocular Therapeutics, Stock

**Rajeev Muni, MD, MSC, FRCS(C), FASRS:** Alcon, Consultant; AbbVie, Consultant; Bayer, Consultant; Novartis, Consultant; Roche, Consultant; Apellis, Consultant; Bausch + Lomb, Consultant